Published in Am J Respir Crit Care Med on July 15, 2015
An Important Step Forward, but Still a Way to Go. Am J Respir Crit Care Med (2016) 1.29
Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis? Am J Respir Crit Care Med (2016) 1.08
Idiopathic Pulmonary Fibrosis and Prothrombotic State. Am J Respir Crit Care Med (2016) 0.98
Update on diagnosis and treatment of idiopathic pulmonary fibrosis. J Bras Pneumol (2015) 0.92
Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med (2015) 0.88
Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now? Drugs (2016) 0.85
Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS One (2016) 0.84
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. Biomed Res Int (2015) 0.83
Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development? BMC Med (2016) 0.83
Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients. Medicine (Baltimore) (2015) 0.81
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. Am J Respir Crit Care Med (2016) 0.81
The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung Disease. J Immunol (2016) 0.80
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med (2016) 0.79
New perspectives on management of idiopathic pulmonary fibrosis. Ther Adv Chronic Dis (2016) 0.79
SH2 Domain-containing Phosphatase-SHP-2 is a Novel Anti-fibrotic Regulator in Pulmonary Fibrosis. Am J Respir Crit Care Med (2016) 0.79
High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease. Front Pharmacol (2016) 0.79
Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Des Devel Ther (2015) 0.79
Managing comorbidities in idiopathic pulmonary fibrosis. Int J Gen Med (2015) 0.79
Idiopathic pulmonary fibrosis: moving forward. BMC Med (2015) 0.79
The Protective Effect of Naringin against Bleomycin-Induced Pulmonary Fibrosis in Wistar Rats. Pulm Med (2016) 0.79
Idiopathic Pulmonary Fibrosis: Novel Concepts of Proton Pump Inhibitors as Antifibrotic Drugs. Am J Respir Crit Care Med (2016) 0.78
Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. Biomed Res Int (2015) 0.78
Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres. BMC Pulm Med (2016) 0.78
Recent advances in understanding idiopathic pulmonary fibrosis. F1000Res (2016) 0.78
Idiopathic Pulmonary Fibrosis: Treatment and Prognosis. Clin Med Insights Circ Respir Pulm Med (2016) 0.77
Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2016) 0.77
Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology (2016) 0.77
HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway. J Cell Mol Med (2016) 0.76
Recommendations for the management of idiopathic pulmonary fibrosis in South Africa: a position statement of the South African Thoracic Society. J Thorac Dis (2016) 0.76
Protective and therapeutic effect of felodipine against bleomycin-induced pulmonary fibrosis in mice. Sci Rep (2017) 0.75
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. Pharmacoeconomics (2017) 0.75
A case of anti-aminoacyl tRNA synthetase (ARS) antibody-positive polymyositis (PM)/dermatomyositis (DM)-associated interstitial pneumonia (IP) successfully controlled with bosentan therapy. Respir Med Case Rep (2017) 0.75
Role of pirfenidone in the management of pulmonary fibrosis. Ther Clin Risk Manag (2017) 0.75
The Airway in Idiopathic Pulmonary Fibrosis: Protecting the Lung or Promoting Disease? Am J Respir Crit Care Med (2016) 0.75
MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Res (2017) 0.75
Utility of Transbronchial versus Surgical Lung Biopsy in the Diagnosis of Suspected Fibrotic Interstitial Lung Disease. Chest (2016) 0.75
Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulm Med (2015) 0.75
Cardiac manifestations of idiopathic pulmonary fibrosis. Intractable Rare Dis Res (2016) 0.75
2016 Respiratory Effectiveness Group Annual Summit Report-impact & influence of real-world respiratory evidence. J Thorac Dis (2016) 0.75
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax (2016) 0.75
Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. J Clin Med (2016) 0.75
Reply to "An Important Step Forward, but Still a Way to Go" and "Idiopathic Pulmonary Fibrosis and Prothrombotic State". Am J Respir Crit Care Med (2016) 0.75
Apolipoprotein A1 Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition of Alveolar Epithelial Cells. Tuberc Respir Dis (Seoul) (2016) 0.75
Taking It Off: New Insights into the Role of Tyrosine Phosphorylation-dependent Pathways in the Pathogenesis of Pulmonary Fibrosis. Am J Respir Crit Care Med (2017) 0.75
Efficacy of antioxidant in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. EXCLI J (2016) 0.75
Reply to "An Important Step Forward, but Still a Way to Go". Am J Respir Crit Care Med (2016) 0.75
Quantification of Pulmonary Fibrosis in a Bleomycin Mouse Model Using Automated Histological Image Analysis. PLoS One (2017) 0.75
Current trends of management of respiratory diseases by pulmonologists: Results of National Conference of Pulmonary Disease - 2015 survey. Lung India (2017) 0.75
3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs. JCI Insight (2017) 0.75
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid (2016) 0.75
Reply: Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis? Am J Respir Crit Care Med (2016) 0.75
Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clin Med Insights Circ Respir Pulm Med (2016) 0.75
miR-30a as Potential Therapeutics by Targeting TET1 through Regulation of Drp-1 Promoter Hydroxymethylation in Idiopathic Pulmonary Fibrosis. Int J Mol Sci (2017) 0.75
A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: A CARE-compliant article. Medicine (Baltimore) (2016) 0.75
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value. Lung (2016) 0.75
Guidelines or guidance for better idiopathic pulmonary fibrosis management? BMC Med (2016) 0.75
Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey. ERJ Open Res (2015) 0.75
Prognostic factors of idiopathic inflammatory myopathies complicated with interstitial lung disease: protocol for a systematic review and meta-analysis. BMJ Open (2016) 0.75
The need for patient-centred clinical research in idiopathic pulmonary fibrosis. BMC Med (2015) 0.75
The Adaptation, Face, and Content Validation of a Needs Assessment Tool: Progressive Disease for People with Interstitial Lung Disease. J Palliat Med (2016) 0.75
Development of a non-infectious rat model of acute exacerbation of idiopathic pulmonary fibrosis. J Thorac Dis (2017) 0.75
Impact of lymphocyte differential count > 15% in BALF on the mortality of patients with acute exacerbation of chronic fibrosing idiopathic interstitial pneumonia. BMC Pulm Med (2017) 0.75
End-of-life care of patients with idiopathic pulmonary fibrosis. BMC Palliat Care (2016) 0.75
Pleural inhibition of the caspase-1/IL-1β pathway diminishes profibrotic lung toxicity of bleomycin. Respir Res (2016) 0.75
Clinical highlights from Amsterdam. ERJ Open Res (2016) 0.75
Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis. Front Med (Lausanne) (2017) 0.75
Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model. Am J Physiol Lung Cell Mol Physiol (2017) 0.75
Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease. Mol Clin Oncol (2017) 0.75
Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view. Korean J Intern Med (2017) 0.75
Idiopathic pulmonary fibrosis in East Asian. Intractable Rare Dis Res (2017) 0.75
A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers. Adv Ther (2017) 0.75
3D Histopathology-a Lung Tissue Segmentation Workflow for Microfocus X-ray-Computed Tomography Scans. J Digit Imaging (2017) 0.75
Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res (2017) 0.75
Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire). Patient (2017) 0.75
Anti-glomerular basement membrane glomerulonephritis following nintedanib for idiopathic pulmonary fibrosis: a case report. J Med Case Rep (2017) 0.75
Fibrotic Hypersensitivity Pneumonitis: Key Issues in Diagnosis and Management. J Clin Med (2017) 0.75
An Official American Thoracic Society Research Statement: Implementation Science in Pulmonary, Critical Care, and Sleep Medicine. Am J Respir Crit Care Med (2016) 0.75
Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis. World J Surg (2017) 0.75
Updated clinical guidelines experience major reporting limitations. Implement Sci (2017) 0.75
Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries. BMC Pulm Med (2017) 0.75
Pirfenidone-induced Eosinophilic Pleurisy. Intern Med (2017) 0.75
BDNF/TrkB axis activation promotes epithelial-mesenchymal transition in idiopathic pulmonary fibrosis. J Transl Med (2017) 0.75
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (2008) 33.10
Grading quality of evidence and strength of recommendations. BMJ (2004) 26.08
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis (2007) 24.91
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med (2005) 23.85
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol (2010) 11.77
ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med (2005) 11.34
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol (2011) 10.02
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med (2006) 9.17
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med (2001) 9.08
Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med (2001) 8.95
ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med (2003) 8.83
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Randomized trials stopped early for benefit: a systematic review. JAMA (2005) 8.43
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J (2013) 8.39
Going from evidence to recommendations. BMJ (2008) 7.30
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20
What is "quality of evidence" and why is it important to clinicians? BMJ (2008) 6.99
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A (2007) 5.95
Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med (2008) 5.82
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol (2010) 5.80
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol (2010) 5.78
Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: a systematic review and meta-analysis. JAMA (2002) 5.57
Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med (2004) 5.56
Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54
Treatment of tuberculosis. MMWR Recomm Rep (2003) 5.41
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med (2012) 5.37
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med (2006) 5.29
Idiopathic pulmonary fibrosis. Lancet (2011) 5.25
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet (2006) 5.19
GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol (2011) 5.10
The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med (2007) 5.06
International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2006) 4.95
A systematic review and meta-analysis of studies comparing mortality rates of private for-profit and private not-for-profit hospitals. CMAJ (2002) 4.84
Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One (2011) 4.65
An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med (2013) 4.49
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40
Mechanisms of pulmonary fibrosis. Annu Rev Med (2004) 4.37
Need for expertise based randomised controlled trials. BMJ (2005) 4.34
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood (2005) 4.29
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 4.29
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med (2005) 4.06
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med (2009) 4.05
Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med (2005) 4.03
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med (2014) 3.96
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation (2013) 3.90
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med (2005) 3.82
Who uses the patient internet portal? The PatientSite experience. J Am Med Inform Assoc (2005) 3.77
GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol (2010) 3.60
American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med (2003) 3.59
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol (2013) 3.58
GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol (2011) 3.54